Rabies-Progress in Control, Treatment and Prevention. Satellite Symposium. Hong Kong (HKG), 1996/06.
VACCINE. SUPPLEMENT, vol. 15, 1997, page S2-S6, 25 réf., ISSN 1359-5938, GBR
DREESEN (D.W.) *, FU (Z.F.) / préf., WASI (C.) / préf.
Rabies is one of the oldest known diseases of mankind, yet it has been only slightly more than 100 years since Pasteur developed the first vaccine for post-exposure treatment.
Since this first crude nerve tissue vaccine, numerous other rabies vaccines for human use have been developed and used with varying degrees of effectiveness and safety.
When used appropriately, new cell culture vaccines provide nearly 100% protection with a high degree of safety ; yet over 40,000 people world-wide die from rabies each year.
Several pre-and post-exposure controlled vaccine trials and clinical studies have shown that the purified chick embryo cell (PCEC) vaccine, RabipurTM, is as safe and effective as the rabies human diploid cell vaccine (HDCV), which is currently considered the gold standard.
Additionally, PCEC vaccine does not result in immune-mediated hypersensitivity reactions following booster doses seen in about 6% of those receiving HDCV boosters following an initial series of HDCV.
Mots-clés BDSP : Homme, Rage, Virose, Infection, Vaccin
Mots-clés Pascal : Article synthèse, Homme, Rage, Virose, Infection, Vaccin
Mots-clés Pascal anglais : Review, Human, Rabies, Viral disease, Infection, Vaccine
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0503746
Code Inist : 002A05C07. Création : 13/02/1998.